|
|
| Research article summary (published 26 Sep 2009): |
Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Full Abstract
BACKGROUND: Guidelines recommend informing patients about the risks and benefits of prostate cancer screening. We evaluated the medical decision-making process for prostate-specific antigen (PSA) testing. METHODS: We conducted a telephone survey of a randomly selected national sample of 3010 English-speaking US adults 40 years and older. Included in the survey were 375 men who had either undergone or discussed (with health care providers [HCPs]) PSA testing in the previous 2 years. We asked subjects about sociodemographic characteristics, prostate cancer screening discussion features, prostate cancer knowledge, and the importance of various decision factors and sources of information. RESULTS: Overall, 69.9% of subjects discussed screening before making a testing decision, including 14.4% who were not tested. Health care providers most often (64.6%) raised the idea of screening, and 73.4% recommended PSA testing. Health care providers emphasized the pros of testing in 71.4% of discussions but infrequently addressed the cons (32.0%). Although 58.0% of subjects felt well-informed about PSA testing, 47.8% failed to correctly answer any of the 3 knowledge questions. Only 54.8% of subjects reported being asked for their screening preferences. An HCP recommendation (odds ratio, 2.67; 95% confidence interval, 1.08-6.58) was the only discussion characteristic associated with testing. Valuing HCP information was also associated with testing (odds ratio, 1.26; 95% confidence interval, 1.04-1.54). CONCLUSIONS: Recommendations and information from HCPs strongly influenced testing decisions. However, most prostate cancer screening decisions did not meet criteria for shared decision making because subjects did not receive balanced discussions of decision consequences, had limited knowledge, and were not routinely asked for their preferences.
Author information
Author/s: Hoffman, Richard M (RM); Couper, Mick P (MP); Zikmund-Fisher, Brian J (BJ); Levin, Carrie A (CA); McNaughton-Collins, Mary (M); Helitzer, Deborah L (DL); VanHoewyk, John (J); Barry, Michael J (MJ);
Affiliation: Medicine Services, New Mexico VA Health Care System, Albuquerque, USA. rhoffman(-atsign-)unm.edu
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal: Archives of internal medicine (Arch Intern Med), published in United States. (Language: eng)
Reference: 2009-Sep; vol 169 (issue 17) : pp 1611-8
Dates: Created 2009/09/29; Completed 2009/10/15;
PMID: 19786681, status: MEDLINE (last retrieval date: 10/15/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
Comments and Corrections
CommentIn: Arch Intern Med. 2009 Sep 28;169(17):1554-6. (PMID: 19786672)
CommentIn: Arch Intern Med. 2009 Sep 28;169(17):1557-9. (PMID: 19786673)
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- A randomized controlled trial of shared decision making for prostate cancer screening.
29 Jun 1999 - To screen or not to screen? Prostate cancer screening: why it's not for every man.
Aug 2008 - Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
8 Apr 2004 - Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
13 Sep 2003 - Screening and early detection for prostate cancer.
29 Sep 1997 - The problem with choice: what my mechanic taught me about PSA screening.
30 Aug 2008 - Prostate cancer screening: accepting the consequences of PSA testing.
30 Mar 1993 - Part 2: Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing.
30 Mar 2005 - Screening for prostate cancer: the role of prostate-specific antigen.
30 Oct 1996 - Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer.
30 Jan 1997
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.